1-nitroxanthone | 17607-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-nitroxanthone
• 英文别名: 1-nitro-xanthen-9-one；1-Nitro-xanthen-9-on；nitroxanthone；1-nitroxanthen-9-one
• CAS: 17607-01-1
• 化学式: C₁₃H₇NO₄
• 分子量: 241.203
• InChiKey: LMZMQXGQDGYBIS-UHFFFAOYSA-N

物化性质

• 熔点：
  127 °C
• 沸点：
  436.4±34.0 °C(Predicted)
• 密度：
  1.457±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-nitroxanthone 在 盐酸 、 sodium hydroxide 、 sodium ethanolate 、 镍 、 tin(ll) chloride 、 三氯氧磷 作用下， 生成 chromeno[4,3,2-de]quinoline
  参考文献：
  名称：

  Camps Reaction with 1-Xanthonamine

  摘要：

  DOI：

  10.1021/ja01178a521
• 作为产物：
  描述：

  2-(3-硝基苯氧基)苯甲酸 在 硫酸 作用下， 生成 1-nitroxanthone
  参考文献：
  名称：

  Julia, Bulletin de la Societe Chimique de France, 1952, p. 546,549

  摘要：

  DOI：

文献信息

• Synthesis and Biological Evaluation of Biphenyl Amides That Modulate the US28 Receptor
  作者：Ana Kralj、Elif Kurt、Nuska Tschammer、Markus R. Heinrich

  DOI：10.1002/cmdc.201300369

  日期：2014.1

  To prepare and biologically evaluate 38 new potential US28 allosteric modulators, we employed a straightforward synthetic route involving radical arylation. The study was based on a former lead structure but with the dihydroisoquinolinone moiety replaced by substituted biphenyls. The investigation of structure–activity relationships among the new biphenyl‐derived ligands led to a preliminary pharmacophore

  为了制备和生物学评估38种潜在的US28变构调节剂，我们采用了一种涉及自由基芳基化的简单合成途径。该研究基于以前的铅结构，但二氢异喹啉酮部分被取代的联苯取代。对新的联苯衍生配体之间的构效关系的研究导致了初步的药效团模型，并发现了四个具有完全反向激动剂特性的有前途的候选物。
• Tetrazolyl substituted tricyclic compounds and pharmacological
  申请人：Burroughs Welcome Co.

  公开号：US04902701A1

  公开（公告）日：1990-02-20

  Tricyclic compounds of formula (I) ##STR1## wherein X.sup.1 is a carboxyl or 5-tetrazolyl group X.sup.2 is carbonyl or methylene X.sup.3 is hydroxyl or a group --X.sup.4 (C.sub.n H.sub.2n)X.sup.5 where X.sup.4 is oxygen or sulphur X.sup.5 is hydrogen or a group --OX.sup.6 where X.sup.6 is hydrogen, alkanoyl of 1 to 4 carbon atoms or a group --(C.sub.m H.sub.2m)X.sup.7 where X.sup.7 is hydrogen or a group --OX.sup.8 where X.sup.8 is hydrogen or alkanoyl of 1 to 4 carbon atoms and m and n are each, independently, an integer from 1 to 4, together with salts thereof, provided that when X.sup.5 is a group --OX.sup.6 then n is always greater than 1 and X.sup.4 and X.sup.5 are attached to different carbon atoms and that when X.sup.7 is a group --OX.sup.8 then m is always greater than 1 and no single carbon atom in the radical --(C.sub.m H.sub.2m)-- is attached to two oxygen atoms. These compounds are of value in medicine in circumstances where it is desirable to provide a more effective delivery of oxygen to the tissues; in vivo applications include the relief or amelioration of tissue hypoxia as in, for example, cardiac or cerebral ischaemia while in vitro they maintain the oxygen-delivery capacity of stored red blood cells and prolong the cells' useful storage life. The invention is also directed to methods for the preparation of the compounds, to pharmaceutical formulations and other presentation forms containing them and the preparation thereof, to the use of the compound in medicine, and to novel intermediates for the said compounds and the preparation thereof.

  式（I）的三环化合物##STR1##其中X.sup.1是羧基或5-四唑基团，X.sup.2是酰基或亚甲基，X.sup.3是羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟
• Tricyclic compounds, preparation, use and intermediates
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0093381A1

  公开（公告）日：1983-11-09

  Tricyclic compounds of formula (I) wherein X' is a carboxyl or 5-tetrazolyl group X2 is carbonyl or methylene X3 is hydroxyl or a group -X4(CnH2n)X5 where X4 is oxygen or sulphur X6 is hydrogen or a group -OX6 where X6 is hydrogen, alkanoyl of 1 to 4 carbon atoms or a group -(CmH2m)X7 where X7 is hydrogen or a group -OX8 where X8 is hydrogen or alkanoyl of 1 to 4 carbon atoms and m and n are each, independently, an integer from 1 to 4, together with salts thereof, provided that when X5 is a group -OX6 then n is always greater than 1 and X4 and X5 are attached to different carbon atoms and that when X7 is a group -OX8 then m is always greater than 1 and no single carbon atom in the radical -(CmH2m)-is attached to two oxygen atoms. These compounds are of value in medicine in circumstances where it is desirable to provide a more effective delivery of oxygen to the tissues; in vivo applications include the relief or amelioration of tissue hypoxia as in, for example, cardiac or cerebral ischaemia while in vitro they maintain the oxygen-delivery capacity of stored red blood cells and prolong the cells' useful storage life. The invention is also directed to methods for the preparation of the compounds, to pharmaceutical formulations and other presentation forms containing them and the preparation thereof, to the use of the compounds in medicine, and to novel intermediates for the said compounds and the preparation thereof.

  式 (I) 的三环化合物 其中 X' 是羧基或 5-四唑基 X2 是羰基或亚甲基 X3 是羟基或基团 -X4(CnH2n)X5 其中 X4 是氧或硫 X6 是氢或基团 -OX6 其中 X6 是氢、1 至 4 个碳原子的烷酰基或基团-(CmH2m)X7 其中 X7 是氢或基团 -OX8 其中 X8 是氢或 1 至 4 个碳原子的烷酰基，m 和 n 各自独立地为 1 至 4 的整数，以及它们的盐、 条件是当 X5 为基团-OX6 时，n 始终大于 1，且 X4 和 X5 连接在不同的碳原子上 当 X7 为基团-OX8 时，m 始终大于 1，且自由基-(CmH2m)-中没有单个碳原子与两个氧原子相连。 这些化合物在医学上的应用价值在于，可以更有效地向组织输送氧气；在体内的应用包括缓解或改善组织缺氧，如心肌或脑缺血，而在体外的应用则是保持储存的红细胞的氧气输送能力，延长细胞的有效储存寿命。 本发明还涉及这些化合物的制备方法、含有这些化合物的药物制剂和其他呈现形式及其制备方法、这些化合物在医学中的用途，以及上述化合物的新型中间体及其制备方法。
• Non-linear optical device
  申请人：HITACHI, LTD.

  公开号：EP0315140A2

  公开（公告）日：1989-05-10

  According to the present invention, there is provided a non-linear optical device comprising a non-linear optical medium comprising an organic compound, which remarkably improves the non-linear optical properties. The non-linear optical device according to the present invention is suited for the second and third harmonic generations, photomixing optical parametric oscillations, optical switches and optical bistable devices.

  根据本发明，提供了一种非线性光学器件，它包括一种由有机化合物组成的非线性光学介质，可显著改善非线性光学特性。本发明的非线性光学器件适用于二次和三次谐波代、光混合光学参量振荡、光学开关和光学双稳态器件。
• Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0532054A1

  公开（公告）日：1993-03-17

  Cognitive defeciencies or neurological dysfunction in mammals are treated with α,α-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: or a salt thereof    wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is α to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;    one of Het¹ or Het² is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from (a) 2, 3, or 4-pyridyl, (b) 2, 4, or 5-pyrimidinyl, (c) 2-pyrazinyl, (d) 3, or 4-pyridazinyl, (e) 3, or 4-pyrazolyl, (f) 2, or 3-tetrahydrofuranyl, and (g) 3-thienyl.

  α，α-二取代芳香族或杂芳族化合物可治疗哺乳动物的认知缺陷或神经功能障碍。这些化合物的化学式如下 或其盐 其中 X 和 Y 共同形成饱和或不饱和碳环或杂环的第一环，所述环中所示碳与融 入第一环的至少一个附加芳环或杂芳环相连； Het¹ 或 Het² 中的一个是 2、3 或 4-吡啶基或 2、4 或 5-嘧啶基，另一个选自以下各项 (a) 2、3 或 4-吡啶基、 (b) 2、4 或 5-嘧啶基、 (c) 2-吡嗪基、 (d) 3 或 4-哒嗪基、 (e) 3 或 4-吡唑基、 (f) 2 或 3-四氢呋喃基，以及 (g) 3-噻吩基。

表征谱图